The DOI matches its Crossref record; 163 of the 163 references it cites were found in a registry or an index.
Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review
Open accessAbstract
BACKGROUND: Convalescent plasma and hyperimmune immunoglobulin may reduce mortality in patients with viral respiratory diseases, and are being investigated as potential therapies for coronavirus disease 2019 (COVID-19). A thorough understanding of the current body of evidence regarding benefits and risks of these interventions is required. OBJECTIVES: Using a living systematic review approach, to assess whether convalescent plasma or hyperimmune immunoglobulin transfusion is effective and safe in the treatment of people with COVID-19; and to maintain the currency of the evidence. SEARCH METHODS: To identify completed and ongoing studies, we searched the World Health Organization (WHO) COVID-19 Global literature on coronavirus disease Research Database, MEDLINE, Embase, the Cochrane COVID-19 Study Register, the Epistemonikos COVID-19 L*OVE Platform, and trial registries. Searches were done on 17 March 2021. SELECTION CRITERIA: We included randomised controlled trials (RCTs) evaluating convalescent plasma or hyperimmune immunoglobulin for COVID-19, irrespective of disease severity, age, gender or ethnicity. For safety assessments, we also included non-controlled non-randomised studies of interventions (NRSIs) if 500 or more participants were included. We excluded studies that included populations with other coronavirus diseases (severe acute respiratory syndrome (SARS) or Middle East respiratory syndrome (MERS)), as well as studies evaluating standard immunoglobulin. DATA COLLECTION AND ANALYSIS: We followed standard Cochrane methodology. To assess bias in included studies, we used the Cochrane 'Risk of Bias 2' tool for RCTs, and for NRSIs, the assessment criteria for observational studies, provided by Cochrane Childhood Cancer. We rated the certainty of evidence, using the GRADE approach, for the following outcomes: all-cause mortality, improvement and worsening of clinical status (for individuals with moderate to severe disease), development of severe clinical COVID-19 symptoms (for individuals with asymptomatic or mild disease), quality of life (including fatigue and functional independence), grade 3 or 4 adverse events, and serious adverse events. MAIN RESULTS: We included 13 studies (12 RCTs, 1 NRSI) with 48,509 participants, of whom 41,880 received convalescent plasma. We did not identify any completed studies evaluating hyperimmune immunoglobulin. We identified a further 100 ongoing studies evaluating convalescent plasma or hyperimmune immunoglobulin, and 33 studies reporting as being completed or terminated. Individuals with a confirmed diagnosis of COVID-19 and moderate to severe disease Eleven RCTs and one NRSI investigated the use of convalescent plasma for 48,349 participants with moderate to severe disease. Nine RCTs compared convalescent plasma to placebo treatment or standard care alone, and two compared convalescent plasma to standard plasma (results not included in abstract). Effectiveness of convalescent plasma We included data on nine RCTs (12,875 participants) to assess the effectiveness of convalescent plasma compared to placebo or standard care alone. Convalescent plasma does not reduce all-cause mortality at up to day 28 (risk ratio (RR) 0.98, 95% confidence interval (CI) 0.92 to 1.05; 7 RCTs, 12,646 participants; high-certainty evidence). It has little to no impact on clinical improvement for all participants when assessed by liberation from respiratory support (RR not estimable; 8 RCTs, 12,682 participants; high-certainty evidence). It has little to no impact on the chance of being weaned or liberated from invasive mechanical ventilation for the subgroup of participants requiring invasive mechanical ventilation at baseline (RR 1.04, 95% CI 0.57 to 1.93; 2 RCTs, 630 participants; low-certainty evidence). It does not reduce the need for invasive mechanical ventilation (RR 0.98, 95% CI 0.89 to 1.08; 4 RCTs, 11,765 participants; high-certainty evidence). We did not identify any subgroup differences. We did not identify any studies reporting quality of life, and therefore, do not know whether convalescent plasma has any impact on quality of life. One RCT assessed resolution of fatigue on day 7, but we are very uncertain about the effect (RR 1.21, 95% CI 1.02 to 1.42; 309 participants; very low-certainty evidence). Safety of convalescent plasma We included results from eight RCTs, and one NRSI, to assess the safety of convalescent plasma. Some of the RCTs reported on safety data only for the convalescent plasma group. We are uncertain whether convalescent plasma increases or reduces the risk of grade 3 and 4 adverse events (RR 0.90, 95% CI 0.58 to 1.41; 4 RCTs, 905 participants; low-certainty evidence), and serious adverse events (RR 1.24, 95% CI 0.81 to 1.90; 2 RCTs, 414 participants; low-certainty evidence). A summary of reported events of the NRSI (reporting safety data for 20,000 of 35,322 transfused participants), and four RCTs reporting safety data only for transfused participants (61
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu, X., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30183-5 · Cited by 48,884
RoB 2: a revised tool for assessing risk of bias in randomised trials
Sterne, J. A. C., Savović, J., Page, M. J., Elbers, R. G., Blencowe, N. S., Boutron, I., Cates, C. J., Cheng, H.-Y., Corbett, M. S., Eldridge, S. M., et al. (2019) · BMJ · doi:10.1136/bmj.l4898 · Cited by 34,787
ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions
Sterne, J. A., Hernán, M. A., Reeves, B. C., Savović, J., Berkman, N. D., Viswanathan, M., Henry, D., Altman, D. G., Ansari, M. T., Boutron, I., et al. (2016) · BMJ · doi:10.1136/bmj.i4919 · Cited by 20,329
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
Moher, D., Liberati, A., Tetzlaff, J., & Altman, D. G. (2009) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2009.06.005 · Cited by 19,575
Cochrane Handbook for Systematic Reviews of Interventions
(2019) · doi:10.1002/9781119536604 · Cited by 14,828
Dexamethasone in Hospitalized Patients with Covid-19
The RECOVERY Collaborative Group (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2021436 · Cited by 11,477
Pathological findings of COVID-19 associated with acute respiratory distress syndrome
Xu, Z., Shi, L., Wang, Y., Zhang, J., Huang, L., Zhang, C., Liu, S., Zhao, P., Liu, H., Zhu, L., et al. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30076-x · Cited by 8,545
GRADE guidelines: 3. Rating the quality of evidence
Balshem, H., Helfand, M., Schünemann, H. J., Oxman, A. D., Kunz, R., Brozek, J., Vist, G. E., Falck-Ytter, Y., Meerpohl, J., & Norris, S. (2011) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2010.07.015 · Cited by 8,285
Wu, C., Chen, X., Cai, Y., Xia, J., Zhou, X., Xu, S., Huang, H., Zhang, L., Zhou, X., Du, C., et al. (2020) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2020.0994 · Cited by 8,249
Remdesivir for the Treatment of Covid-19 — Final Report
Beigel, J. H., Tomashek, K. M., Dodd, L. E., Mehta, A. K., Zingman, B. S., Kalil, A. C., Hohmann, E., Chu, H. Y., Luetkemeyer, A., Kline, S., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2007764 · Cited by 7,267
Cumpston, M., Li, T., Page, M. J., Chandler, J., Welch, V. A., Higgins, J. P., & Thomas, J. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.ed000142 · Cited by 7,218
Factors associated with COVID-19-related death using OpenSAFELY
Williamson, E. J., Walker, A. J., Bhaskaran, K., Bacon, S., Bates, C., Morton, C. E., Curtis, H. J., Mehrkar, A., Evans, D., Inglesby, P., et al. (2020) · Nature · doi:10.1038/s41586-020-2521-4 · Cited by 6,674
Practical methods for incorporating summary time-to-event data into meta-analysis.
Tierney, J. F., Stewart, L. A., Ghersi, D., Burdett, S., & Sydes, M. R. (2007) · Trials · doi:10.1186/1745-6215-8-16 · Cited by 6,208
Lauer, S. A., Grantz, K. H., Bi, Q., Jones, F. K., Zheng, Q., Meredith, H. R., Azman, A. S., Reich, N. G., & Lessler, J. (2020) · Annals of Internal Medicine · doi:10.7326/m20-0504 · Cited by 5,970
McGuinness, L. A., & Higgins, J. P. T. (2021) · Research Synthesis Methods · doi:10.1002/jrsm.1411 · Cited by 5,579
Parmar, M. K. B., Torri, V., & Stewart, L. (1998) · Statistics in Medicine · doi:10.1002/(sici)1097-0258(19981230)17:24<2815::aid-sim110>3.0.co;2-8 · Cited by 4,802
Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China
Liang, W., Guan, W., Chen, R., Wang, W., Li, J., Xu, K., Li, C., Ai, Q., Lu, W., Liang, H., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30096-6 · Cited by 4,384
(2008) · Cited by 3,790
(2020) · PubMed · doi:10.3760/cma.j.issn.0254-6450.2020.02.003 · Cited by 3,323
CDC Weekly, C., & The Novel Coronavirus Pneumonia Emergency Response Epidemiology Team (2020) · China CDC Weekly · doi:10.46234/ccdcw2020.032 · Cited by 2,889
Analysing data and undertaking meta‐analyses
Deeks, J. J., Higgins, J. P., Altman, D. G., & on behalf of the Cochrane Statistical Methods Group (2019) · Cochrane Handbook for Systematic Reviews of Interventions · doi:10.1002/9781119536604.ch10 · Cited by 2,672
Antibody Responses to SARS-CoV-2 in Patients With Novel Coronavirus Disease 2019
Zhao, J., Yuan, Q., Wang, H., Liu, W., Liao, X., Su, Y., Wang, X., Yuan, J., Li, T., Li, J., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa344 · Cited by 2,607
Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma
Shen, C., Wang, Z., Zhao, F., Yang, Y., Li, J., Yuan, J., Wang, F., Li, D., Yang, M., Xing, L., et al. (2020) · JAMA · doi:10.1001/jama.2020.4783 · Cited by 2,277
Driggin, E., Madhavan, M. V., Bikdeli, B., Chuich, T., Laracy, J., Biondi-Zoccai, G., Brown, T. S., Der Nigoghossian, C., Zidar, D. A., Haythe, J., et al. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.03.031 · Cited by 2,017
Abani, O., Abbas, A., Abbas, F., Abbas, M., Abbasi, S., Abbass, H., Abbott, A., Abdallah, N., Abdelaziz, A., Abdelfattah, M., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00676-0 · Cited by 1,983
Effectiveness of convalescent plasma therapy in severe COVID-19 patients
Duan, K., Liu, B., Li, C., Zhang, H., Yu, T., Qu, J., Zhou, M., Chen, L., Meng, S., Hu, Y., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2004168117 · Cited by 1,960
Convergent Antibody Responses to SARS-CoV-2 in Convalescent Individuals
Robbiani, D. F., Gaebler, C., Muecksch, F., Lorenzi, J. C. C., Wang, Z., Cho, A., Agudelo, M., Barnes, C. O., Gazumyan, A., Finkin, S., et al. (2020) · Nature · doi:10.1038/s41586-020-2456-9 · Cited by 1,853
Assessing risk of bias in a randomized trial
Higgins, J. P., Savović, J., Page, M. J., Elbers, R. G., & Sterne, J. A. (2019) · Cochrane Handbook for Systematic Reviews of Interventions · doi:10.1002/9781119536604.ch8 · Cited by 1,765
A minimal common outcome measure set for COVID-19 clinical research
Marshall, J. C., Murthy, S., Diaz, J., Adhikari, N. K., Angus, D. C., Arabi, Y. M., Baillie, K., Bauer, M., Berry, S., Blackwood, B., et al. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30483-7 · Cited by 1,641
Remdesivir for the Treatment of Covid-19 — Preliminary Report
(2020) · New England Journal of Medicine · doi:10.1056/nejmc2022236 · Cited by 1,396
World Health Organization (2020) · Pediatria i Medycyna Rodzinna · doi:10.15557/pimr.2020.0003 · Cited by 1,329
The Novel Coronavirus Pneumonia Emergency Response Epidemiology Team (2020) · PubMed Central · Cited by 1,278
Li, L., Zhang, W., Hu, Y., Tong, X., Zheng, S., Yang, J., Kong, Y., Ren, L., Wei, Q., Mei, H., et al. (2020) · JAMA · doi:10.1001/jama.2020.10044 · Cited by 1,206
Santesso, N., Glenton, C., Dahm, P., Garner, P., Akl, E. A., Alper, B., Brignardello-Petersen, R., Carrasco-Labra, A., De Beer, H., Hultcrantz, M., et al. (2020) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2019.10.014 · Cited by 1,198
Self-citationConvalescent plasma as a potential therapy for COVID-19
Chen, L., Xiong, J., Bao, L., & Shi, Y. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30141-9 · Cited by 1,038
Mair-Jenkins, J., Saavedra-Campos, M., Baillie, J. K., Cleary, P., Khaw, F.-M., Lim, W. S., Makki, S., Rooney, K. D., Convalescent Plasma Study Group, Nguyen-Van-Tam, J. S., et al. (2015) · Journal of Infectious Diseases · doi:10.1093/infdis/jiu396 · Cited by 983
Choosing effect measures and computing estimates of effect
Higgins, J. P., Li, T., & Deeks, J. J. (2019) · Cochrane Handbook for Systematic Reviews of Interventions · doi:10.1002/9781119536604.ch6 · Cited by 977
Schünemann, H. J., Cuello, C., Akl, E. A., Mustafa, R. A., Meerpohl, J. J., Thayer, K., Morgan, R. L., Gartlehner, G., Kunz, R., Katikireddi, S. V., et al. (2019) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2018.01.012 · Cited by 911
A Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia
Simonovich, V. A., Burgos Pratx, L. D., Scibona, P., Beruto, M. V., Vallone, M. G., Vázquez, C., Savoy, N., Giunta, D. H., Pérez, L. G., Sánchez, M. D. L., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2031304 · Cited by 907
The convalescent sera option for containing COVID-19
Casadevall, A., & Pirofski, L.-A. (2020) · Journal of Clinical Investigation · doi:10.1172/jci138003 · Cited by 903
Early High-Titer Plasma Therapy to Prevent Severe Covid-19 in Older Adults
Libster, R., Pérez Marc, G., Wappner, D., Coviello, S., Bianchi, A., Braem, V., Esteban, I., Caballero, M. T., Wood, C., Berrueta, M., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2033700 · Cited by 873
Deployment of convalescent plasma for the prevention and treatment of COVID-19
Bloch, E. M., Shoham, S., Casadevall, A., Sachais, B. S., Shaz, B., Winters, J. L., van Buskirk, C., Grossman, B. J., Joyner, M., Henderson, J. P., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci138745 · Cited by 799
Wu, F., Wang, A., Liu, M., Wang, Q., Chen, J., Xia, S., Ling, Y., Zhang, Y., Xun, J., Lu, L., et al. (2020) · doi:10.1101/2020.03.30.20047365 · Cited by 754
Agarwal, A., Mukherjee, A., Kumar, G., Chatterjee, P., Bhatnagar, T., & Malhotra, P. (2020) · BMJ · doi:10.1136/bmj.m3939 · Cited by 718
Coronavirus fulminant myocarditis treated with glucocorticoid and human immunoglobulin
Hu, H., Ma, F., Wei, X., & Fang, Y. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehaa190 · Cited by 687
Coronaviruses and Immunosuppressed Patients: The Facts During the Third Epidemic
D’Antiga, L. (2020) · Liver Transplantation · doi:10.1002/lt.25756 · Cited by 664
Molecular Mechanism for Antibody-Dependent Enhancement of Coronavirus Entry
Wan, Y., Shang, J., Sun, S., Tai, W., Chen, J., Geng, Q., He, L., Chen, Y., Wu, J., Shi, Z., et al. (2020) · Journal of Virology · doi:10.1128/jvi.02015-19 · Cited by 662
Searching for and selecting studies
Lefebvre, C., Glanville, J., Briscoe, S., Littlewood, A., Marshall, C., Metzendorf, M., Noel‐Storr, A., Rader, T., Shokraneh, F., Thomas, J., et al. (2019) · Cochrane Handbook for Systematic Reviews of Interventions · doi:10.1002/9781119536604.ch4 · Cited by 647
Meta-Analysis: Convalescent Blood Products for Spanish Influenza Pneumonia: A Future H5N1 Treatment?
Luke, T. C., Kilbane, E. M., Jackson, J. L., & Hoffman, S. L. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-145-8-200610170-00139 · Cited by 636
Interpreting results and drawing conclusions
Schünemann, H. J., Vist, G. E., Higgins, J. P., Santesso, N., Deeks, J. J., Glasziou, P., Akl, E. A., Guyatt, G. H., & on behalf of the Cochrane GRADEing Methods Group (2019) · Cochrane Handbook for Systematic Reviews of Interventions · doi:10.1002/9781119536604.ch15 · Cited by 595
COVID-19 in Immunocompromised Hosts: What We Know So Far
Fung, M., & Babik, J. M. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa863 · Cited by 526
Convalescent Plasma Antibody Levels and the Risk of Death from Covid-19
Joyner, M. J., Carter, R. E., Senefeld, J. W., Klassen, S. A., Mills, J. R., Johnson, P. W., Theel, E. S., Wiggins, C. C., Bruno, K. A., Klompas, A. M., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2031893 · Cited by 509
Convalescent plasma treatment of severe COVID-19: a propensity score–matched control study
Liu, S. T. H., Lin, H.-M., Baine, I., Wajnberg, A., Gumprecht, J. P., Rahman, F., Rodriguez, D., Tandon, P., Bassily-Marcus, A., Bander, J., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-1088-9 · Cited by 493
Early safety indicators of COVID-19 convalescent plasma in 5000 patients
Joyner, M. J., Wright, R. S., Fairweather, D., Senefeld, J. W., Bruno, K. A., Klassen, S. A., Carter, R. E., Klompas, A. M., Wiggins, C. C., Shepherd, J. R. A., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci140200 · Cited by 471
Angus, D. C., Berry, S., Lewis, R. J., Al-Beidh, F., Arabi, Y., van Bentum-Puijk, W., Bhimani, Z., Bonten, M., Broglio, K., Brunkhorst, F., et al. (2020) · Annals of the American Thoracic Society · doi:10.1513/annalsats.202003-192sd · Cited by 446
Antibody-dependent SARS coronavirus infection is mediated by antibodies against spike proteins
Wang, S.-F., Tseng, S.-P., Yen, C.-H., Yang, J.-Y., Tsao, C.-H., Shen, C.-W., Chen, K.-H., Liu, F.-T., Liu, W.-T., Chen, Y.-M. A., et al. (2014) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2014.07.090 · Cited by 421
Zhang, B., Liu, S., Tan, T., Huang, W., Dong, Y., Chen, L., Chen, Q., Zhang, L., Zhong, Q., Zhang, X., et al. (2020) · Chest · doi:10.1016/j.chest.2020.03.039 · Cited by 420
Lack of Reinfection in Rhesus Macaques Infected with SARS-CoV-2
Bao, L., Deng, W., Gao, H., Xiao, C., Liu, J., Xue, J., Lv, Q., Liu, J., Yu, P., Xu, Y., et al. (2020) · doi:10.1101/2020.03.13.990226 · Cited by 419
Treatment with convalescent plasma for COVID‐19 patients in Wuhan, China
Ye, M., Fu, D., Ren, Y., Wang, F., Wang, D., Zhang, F., Xia, X., & Lv, T. (2020) · Journal of Medical Virology · doi:10.1002/jmv.25882 · Cited by 410
Cao, W., Liu, X., Bai, T., Fan, H., Hong, K., Song, H., Han, Y., Lin, L., Ruan, L., & Li, T. (2020) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofaa102 · Cited by 405
Joyner, M. J., Bruno, K. A., Klassen, S. A., Kunze, K. L., Johnson, P. W., Lesser, E. R., Wiggins, C. C., Senefeld, J. W., Klompas, A. M., Hodge, D. O., et al. (2020) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2020.06.028 · Cited by 398
Robbins, J. B., Schneerson, R., & Szu, S. C. (1995) · Journal of Infectious Diseases · doi:10.1093/infdis/171.6.1387 · Cited by 385
Ahn, J. Y., Sohn, Y., Lee, S. H., Cho, Y., Hyun, J. H., Baek, Y. J., Jeong, S. J., Kim, J. H., Ku, N. S., Yeom, J.-S., et al. (2020) · Journal of Korean Medical Science · doi:10.3346/jkms.2020.35.e149 · Cited by 352
Adverse effects of plasma transfusion
Pandey, S., & Vyas, G. N. (2012) · Transfusion · doi:10.1111/j.1537-2995.2012.03663.x · Cited by 351
Gharbharan, A., Jordans, C. C. E., GeurtsvanKessel, C., den Hollander, J. G., Karim, F., Mollema, F. P. N., Stalenhoef – Schukken, J. E., Dofferhoff, A., Ludwig, I., Koster, A., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-23469-2 · Cited by 347
Joyner, M. J., Senefeld, J. W., Klassen, S. A., Mills, J. R., Johnson, P. W., Theel, E. S., Wiggins, C. C., Bruno, K. A., Klompas, A. M., Lesser, E. R., et al. (2020) · medRxiv · doi:10.1101/2020.08.12.20169359 · Cited by 337
Immune responses to influenza virus infection
Kreijtz, J. H. C. M., Fouchier, R. A. M., & Rimmelzwaan, G. F. (2011) · Virus Research · doi:10.1016/j.virusres.2011.09.022 · Cited by 336
Zeng, Q.-L., Yu, Z.-J., Gou, J.-J., Li, G.-M., Ma, S.-H., Zhang, G.-F., Xu, J.-H., Lin, W.-B., Cui, G.-L., Zhang, M.-M., et al. (2020) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiaa228 · Cited by 330
Antibody-Dependent Enhancement of Infection and the Pathogenesis of Viral Disease
Morens, D. M. (1994) · Clinical Infectious Diseases · doi:10.1093/clinids/19.3.500 · Cited by 317
Convalescent Plasma to Treat COVID-19: Possibilities and Challenges
Roback, J. D., & Guarner, J. (2020) · JAMA · doi:10.1001/jama.2020.4940 · Cited by 299
Defining the criteria for including studies and how they will be grouped for the synthesis
McKenzie, J. E., Brennan, S. E., Ryan, R. E., Thomson, H. J., Johnston, R. V., & Thomas, J. (2019) · Cochrane Handbook for Systematic Reviews of Interventions · doi:10.1002/9781119536604.ch3 · Cited by 290
Treatment of Coronavirus Disease 2019 (COVID-19) Patients with Convalescent Plasma
Salazar, E., Perez, K. K., Ashraf, M., Chen, J., Castillo, B., Christensen, P. A., Eubank, T., Bernard, D. W., Eagar, T. N., Long, S. W., et al. (2020) · The American Journal of Pathology · doi:10.1016/j.ajpath.2020.05.014 · Cited by 289
Hyperimmune IV Immunoglobulin Treatment
Hung, I. F. N., To, K. K. W., Lee, C.-K., Lee, K.-L., Yan, W.-W., Chan, K., Chan, W.-M., Ngai, C.-W., Law, K.-I., Chow, F.-L., et al. (2013) · Chest · doi:10.1378/chest.12-2907 · Cited by 286
Adverse Effects of Human Immunoglobulin Therapy
Stiehm, E. R. (2013) · Transfusion Medicine Reviews · doi:10.1016/j.tmrv.2013.05.004 · Cited by 283
Xie, Y., Cao, S., Dong, H., Li, Q., Chen, E., Zhang, W., Yang, L., Fu, S., & Wang, R. (2020) · Journal of Infection · doi:10.1016/j.jinf.2020.03.044 · Cited by 252
Including variants on randomized trials
Higgins, J. P., Eldridge, S., & Li, T. (2019) · Cochrane Handbook for Systematic Reviews of Interventions · doi:10.1002/9781119536604.ch23 · Cited by 243
Janiaud, P., Axfors, C., Schmitt, A. M., Gloy, V., Ebrahimi, F., Hepprich, M., Smith, E. R., Haber, N. A., Khanna, N., Moher, D., et al. (2021) · JAMA · doi:10.1001/jama.2021.2747 · Cited by 239
What reinfections mean for COVID-19
Iwasaki, A. (2021) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30783-0 · Cited by 230
Covid-19: FDA approves use of convalescent plasma to treat critically ill patients
Tanne, J. H. (2020) · BMJ · doi:10.1136/bmj.m1256 · Cited by 224
Antibody Responses to SARS-CoV-2 in Patients of Novel Coronavirus Disease 2019
Zhao, J., Yuan, Q., Wang, H., Liu, W., Liao, X., Su, Y., Wang, X., Yuan, J., Li, T., Li, J., et al. (2020) · SSRN Electronic Journal · doi:10.2139/ssrn.3546052 · Cited by 208
de Assis, R. R., Jain, A., Nakajima, R., Jasinskas, A., Felgner, J., Obiero, J. M., Norris, P. J., Stone, M., Simmons, G., Bagri, A., et al. (2021) · Nature Communications · doi:10.1038/s41467-020-20095-2 · Cited by 205
Persistence of Antibodies against Middle East Respiratory Syndrome Coronavirus
Payne, D. C., Iblan, I., Rha, B., Alqasrawi, S., Haddadin, A., Al Nsour, M., Alsanouri, T., Ali, S. S., Harcourt, J., Miao, C., et al. (2016) · Emerging Infectious Diseases · doi:10.3201/eid2210.160706 · Cited by 201
Avendaño-Solá, C., Ramos-Martínez, A., Muñez-Rubio, E., Ruiz-Antorán, B., Malo de Molina, R., Torres, F., Fernández-Cruz, A., Calderón-Parra, J., Payares-Herrera, C., Díaz de Santiago, A., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci152740 · Cited by 196
MO, H., ZENG, G., REN, X., LI, H., KE, C., TAN, Y., CAI, C., LAI, K., CHEN, R., CHAN‐YEUNG, M., et al. (2006) · Respirology · doi:10.1111/j.1440-1843.2006.00783.x · Cited by 193
Abolghasemi, H., Eshghi, P., Cheraghali, A. M., Imani Fooladi, A. A., Bolouki Moghaddam, F., Imanizadeh, S., Moeini Maleki, M., Ranjkesh, M., Rezapour, M., Bahramifar, A., et al. (2020) · Transfusion and Apheresis Science · doi:10.1016/j.transci.2020.102875 · Cited by 188
Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a rapid review
Valk, S. J., Piechotta, V., Chai, K. L., Doree, C., Monsef, I., Wood, E. M., Lamikanra, A., Kimber, C., McQuilten, Z., So-Osman, C., et al. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013600 · Cited by 182
Self-citationA randomized double-blind controlled trial of convalescent plasma in adults with severe COVID-19
O’Donnell, M. R., Grinsztejn, B., Cummings, M. J., Justman, J. E., Lamb, M. R., Eckhardt, C. M., Philip, N. M., Cheung, Y. K., Gupta, V., João, E., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci150646 · Cited by 179
Including non‐randomized studies on intervention effects
Reeves, B. C., Deeks, J. J., Higgins, J. P. T., Shea, B., Tugwell, P., Wells, G. A., & on behalf of the Cochrane Non‐Randomized Studies of Interventions Methods Group (2019) · Wiley eBooks · doi:10.1002/9781119536604.ch24 · Cited by 175
Collecting and evaluating convalescent plasma for COVID‐19 treatment: why and how?
Tiberghien, P., de Lamballerie, X. N., Morel, P., Gallian, P., Lacombe, K., & Yazdanpanah, Y. (2020) · Vox Sanguinis · doi:10.1111/vox.12926 · Cited by 168
Jawhara, S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21072272 · Cited by 163
An overview of platform trials with a checklist for clinical readers
Park, J., Harari, O., Dron, L., Lester, R. T., Thorlund, K., & Mills, E. J. (2020) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2020.04.025 · Cited by 148
Neutralizing Antibody Response and SARS Severity
Ho, M., Chen, W., Chen, H., Lin, S.-F., Wang, M.-C., Di, J., Lu, Y., Liu, C., Chang, S., Chao, C.-L., et al. (2005) · Emerging infectious diseases · doi:10.3201/eid1111.040659 · Cited by 144
Davey, R. T., Fernández‐Cruz, E., Markowitz, N. P., Pett, S. L., Babiker, A. G., Wentworth, D. N., Khurana, S., Engen, N. W., Gordin, F. M., Jain, M. K., et al. (2019) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(19)30253-x · Cited by 139
Perotti, C., Baldanti, F., Bruno, R., Fante, C. D., Seminari, E. M., Casari, S., Percivalle, E., Glingani, C., Musella, V., Belliato, M., et al. (2020) · Haematologica · doi:10.3324/haematol.2020.261784 · Cited by 136
Zhang, L., Pang, R., Xue, X., Bao, J., Ye, S., Dai, Y., Zheng, Y., Fu, Q., Hu, Z., & Yi, Y. (2020) · Aging · doi:10.18632/aging.103102 · Cited by 133
Use of convalescent plasma in hospitalized patients with COVID-19: case series
Hegerova, L. T., Gooley, T. A., Sweerus, K. A., Maree, C. L., Bailey, N., Bailey, M., Dunleavy, V., Patel, K., Alcorn, K. W., Haley, R., et al. (2020) · Blood · doi:10.1182/blood.2020006964 · Cited by 133
History of Immunoglobulin Replacement
Eibl, M. M. (2008) · Immunology and Allergy Clinics of North America · doi:10.1016/j.iac.2008.06.004 · Cited by 132
Rasheed, A. M., Fatak, D. F., Hashim, H. A., et al. (2020) · PubMed · Cited by 121
AlQahtani, M., Abdulrahman, A., Almadani, A. H., AlAli, S., Alzamrooni, A. M., Hejab, A. H., Conroy, R. M., Wasif, P., Otoom, S. A.-A., Atkin, S. L., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-89444-5 · Cited by 114
Beigel, J. H., Tebas, P., Elie-Turenne, M.-C., Bajwa, E. K., Bell, T. E., Cairns, C. B., Shoham, S., Deville, J. G., Feucht, E. C., Feinberg, J., et al. (2017) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(17)30174-1 · Cited by 113
Shi, H., Zhou, C., He, P., Huang, S., Duan, Y., Wang, X., Lin, K., Chao Hui, Z. H. O. U., Zhang, X., & Zha, Y. (2020) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2020.105974 · Cited by 111
Beigel, J. H., Aga, E., Elie-Turenne, M.-C., Cho, J., Tebas, P., Clark, C. L., Metcalf, J. P., Ozment, C., Raviprakash, K., Beeler, J., et al. (2019) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(19)30199-7 · Cited by 110
Balcells, M. E., Rojas, L. E., Corre, N. L., Martínez-Valdebenito, C., Ceballos, M. E., Marcela Ferrés, G., Chang, M., Vizcaya, C., Mondaca, S., Alvaro Huete, G., et al. (2021) · PLoS Medicine · doi:10.1371/journal.pmed.1003415 · Cited by 109
Middle East Respiratory Syndrome (MERS-CoV): World Health Organization Responses
Salaam-Blyther, T. (2015) · University of North Texas Digital Library (University of North Texas) · Cited by 108
A Randomized Trial of Convalescent Plasma for COVID-19—Potentially Hopeful Signals
Casadevall, A., Joyner, M. J., & Pirofski, L. (2020) · JAMA · doi:10.1001/jama.2020.10218 · Cited by 102
Olfactory Dysfunction in the COVID-19 Outbreak
Izquierdo-Domínguez, A., Rojas‐Lechuga, M. J., Mullol, J., & Alobid, I. (2020) · Journal of Investigational Allergology and Clinical Immunology · doi:10.18176/jiaci.0567 · Cited by 99
Tolouian, R., Vahed, S. Z., Ghiyasvand, S., Tolouian, A., & Ardalan, M. (2020) · Journal of Renal Injury Prevention · doi:10.34172/jrip.2020.19 · Cited by 98
Díez, J.-M., Romero, C. S., & Gajardo, R. (2020) · Immunotherapy · doi:10.2217/imt-2020-0095 · Cited by 97
Ray, Y., Paul, S. R., Bandopadhyay, P., D’Rozario, R., Sarif, J., Raychaudhuri, D., Bhowmik, D., Lahiri, A., Vasudevan, J. S., Maurya, R., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-28064-7 · Cited by 94
Anderson, J., Schauer, J., Bryant, S., & Graves, C. R. (2020) · Case Reports in Women s Health · doi:10.1016/j.crwh.2020.e00221 · Cited by 89
Kinins and Cytokines in COVID-19: A Comprehensive Pathophysiological ApproachPreprint
van de Veerdonk, F. L., Netea, M. G., van Deuren, M., van der Meer, J. W. M., de Mast, Q., Brüggemann, R. J. M., & van der Hoeven, H. (2020) · Preprints.org · doi:10.20944/preprints202004.0023.v1 · Cited by 88
Padilla, E. M., Yarce, O., Ortega, C., Fernández, S., Pascual, N., Gómez, C., Alvarez, M. A., Molina, I. J., Lama, R., & Santamaria, M. L. (2020) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2020.06.046 · Cited by 86
COVID-19 Convalescent Plasma: Now Is the Time for Better Science
Dzik, S. (2020) · Transfusion Medicine Reviews · doi:10.1016/j.tmrv.2020.04.002 · Cited by 85
Skoetz, N., Goldkuhle, M., van Dalen, E. C., Akl, E. A., Trivella, M., Mustafa, R. A., Nowak, A. J., Dahm, P., Schünemann, H. J., & Bender, R. (2019) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2019.10.015 · Cited by 84
Self-citationBandopadhyay, P., D’Rozario, R., Lahiri, A., Sarif, J., Ray, Y., Paul, S. R., Roy, R., Maiti, R., Chaudhuri, K., Bagchi, S., et al. (2021) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiab010 · Cited by 83
A report of clinical diagnosis and treatment of nine cases of coronavirus disease 2019
Chen, Q., Quan, B., Li, X., Gao, G., Zheng, W., Zhang, J., Zhang, Z., Liu, C., Li, L., Wang, C., et al. (2020) · Journal of Medical Virology · doi:10.1002/jmv.25755 · Cited by 77
Understanding and Interpretation of Case Fatality Rate of Coronavirus Disease 2019
Kim, D.-H., Choe, Y. J., & Jeong, J. (2020) · Journal of Korean Medical Science · doi:10.3346/jkms.2020.35.e137 · Cited by 68
Pouladzadeh, M., Safdarian, M., Eshghi, P., Abolghasemi, H., bavani, A. G., Sheibani, B., Choghakabodi, P. M., Feghhi, A., Boroujerdnia, M. G., Forouzan, A., et al. (2021) · Internal and Emergency Medicine · doi:10.1007/s11739-021-02734-8 · Cited by 68
Bennett‐Guerrero, E., Romeiser, J. L., Talbot, L. R., Ahmed, T., Mamone, L. J., Singh, S. M., Hearing, J. C., Salman, H., Holiprosad, D. D., Freedenberg, A. T., et al. (2021) · Critical Care Medicine · doi:10.1097/ccm.0000000000005066 · Cited by 67
Acute Demyelinating Encephalomyelitis (ADEM) in COVID-19 Infection: A Case Series
McCuddy, M., Kelkar, P., Zhao, Y., & Wicklund, D. (2020) · Neurology India · doi:10.4103/0028-3886.299174 · Cited by 66
Madariaga, M. L. L., Guthmiller, J. J., Schrantz, S. J., Jansen, M. O., Christensen, C., Kumar, M., Prochaska, M., Wool, G. D., Celauro, A. D., Oh, W. H., et al. (2020) · Journal of Internal Medicine · doi:10.1111/joim.13185 · Cited by 65
Bajpai, M., Kumar, S., Maheshwari, A., Chhabra, K., Kale, P. R., Gupta, A., Narayanan, A., Gupta, E., Trehanpati, N., Bihari, C., et al. (2022) · Anais da Academia Brasileira de Ciências · doi:10.1590/0001-3765202220210202 · Cited by 64
Peng, H., Gong, T., Huang, X., Sun, X., Luo, H., Wang, W., Luo, J., Luo, B., Chen, Y., Wang, X., et al. (2020) · Stem Cell Research & Therapy · doi:10.1186/s13287-020-01802-8 · Cited by 60
Prolonged viral shedding in a lymphoma patient with COVID-19 infection receiving convalescent plasma
Karataş, A., İnkaya, A. Ç., Demiroğlu, H., Aksu, S., Haziyev, T., Çınar, O. E., Alp, A., Uzun, Ö., Sayınalp, N., & Göker, H. (2020) · Transfusion and Apheresis Science · doi:10.1016/j.transci.2020.102871 · Cited by 58
Chun, S., Chung, C. R., Ha, Y. E., Han, T. H., Ki, C., Kang, E., Park, J. K., Peck, K. R., & Cho, D. (2016) · Annals of Laboratory Medicine · doi:10.3343/alm.2016.36.4.393 · Cited by 55
Operational protocol for donation of anti‐COVID‐19 convalescent plasma in Italy
Franchini, M., Marano, G., Velati, C., Pati, I., Pupella, S., & Liumbruno, G. M. (2020) · Vox Sanguinis · doi:10.1111/vox.12940 · Cited by 53
Ricke, D. O., & Malone, R. W. (2020) · SSRN Electronic Journal · doi:10.20944/preprints202003.0138.v1 · Cited by 52
Convalescent serum lines up as first-choice treatment for coronavirus
Sheridan, C. (2020) · Nature Biotechnology · doi:10.1038/d41587-020-00011-1 · Cited by 49
Hospitalized COVID-19 patients treated with convalescent plasma in a mid-size city in the Midwest
Hartman, W. R., Hess, A. S., & Connor, J. P. (2020) · Translational Medicine Communications · doi:10.1186/s41231-020-00068-9 · Cited by 47
Çınar, O. E., Sayinalp-Arslan, B., Aladağ, E., Karataş, A., Velet, M., İnkaya, A. Ç., Ersoy, N. E. O., Öcal, S., Aksu, S., Haznedaroğlu, İ. C., et al. (2020) · Transfusion and Apheresis Science · doi:10.1016/j.transci.2020.102821 · Cited by 46
A special case of COVID-19 with long duration of viral shedding for 49 daysPreprint
Tan, L., Kang, X., Zhang, B., Zheng, S., Liu, B., Yu, T., Yang, F., Wang, Q., & Miao, H. (2020) · medRxiv · doi:10.1101/2020.03.22.20040071 · Cited by 45
Ibrahim, D., Dulipsingh, L., Zapatka, L., Eadie, R., Crowell, R. E., Williams, K., Wakefield, D. B., Cook, L., Puff, J., & Hussain, S. A. (2020) · Infectious Diseases and Therapy · doi:10.1007/s40121-020-00341-2 · Cited by 43
Barone, P. D., & Desimone, R. A. (2020) · Transfusion · doi:10.1111/trf.15843 · Cited by 42
Hepatic late adverse effects after antineoplastic treatment for childhood cancer
Mulder, R. L., van Dalen, E. C., den Hof, M. V., Leclercq, E., Bresters, D., Koot, B. G. P., Castellino, S. M., Loke, Y. K., Post, P. N., Caron, H. N., et al. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008205.pub2 · Cited by 40
Baudel, J.-L., Vigneron, C., Pras-Landre, V., Joffre, J., Marjot, F., Ait‐Oufella, H., Bigé, N., Maury, É., Guidet, B., Fain, O., et al. (2019) · Clinical Rheumatology · doi:10.1007/s10067-019-04832-7 · Cited by 40
Perotti, C. G., Fante, C. D., Baldanti, F., Franchini, M., Percivalle, E., Nepita, E. V., Seminari, E. M., SILVESTRI, A. D., Bruno, R., & Klersy, C. (2020) · Internal and Emergency Medicine · doi:10.1007/s11739-020-02384-2 · Cited by 40
Genetic Regulation of Fibrinogen
Humphries, S. E. (1995) · European Heart Journal · doi:10.1093/eurheartj/16.suppl_a.16 · Cited by 39
Convalescent Plasma to Treat COVID-19: Chinese Strategy and ExperiencesPreprint
Pei, S., Yuan, X., Zhang, Z., et al. (2020) · medRxiv · doi:10.1101/2020.04.07.20056440 · Cited by 39
Hepatic late adverse effects after antineoplastic treatment for childhood cancer
Mulder, R. L., Bresters, D., den Hof, M. V., Koot, B. G. P., Castellino, S. M., Loke, Y. K., Post, P. N., Postma, A., Szőnyi, L. P., Levitt, G., et al. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008205.pub3 · Cited by 39
Rasheed, A. M., Fatak, D. F., Hashim, H. A., Maulood, M. F., Kabah, K. K., Almusawi, Y. A., & Abdulamir, A. S. (2020) · medRxiv · doi:10.1101/2020.06.24.20121905 · Cited by 36
Tan, L., Kang, X., Zhang, B., Zheng, S., Liu, B., Yu, T., Yang, F., Wang, Q., & Miao, H. (2020) · MedComm · doi:10.1002/mco2.2 · Cited by 33
Coronavirus drugs: Using plasma from recovered patients as a treatment for COVID-19
Alzoughool, F., & Alanagreh, L. (2020) · International Journal of Risk & Safety in Medicine · doi:10.3233/jrs-201017 · Cited by 33
Clinical Features of COVID-19 in a Young Man with Massive Cerebral Hemorrhage—Case Report
Bao, Y., Lin, S. Y., Cheng, Z. H., Xia, J., Sun, Y., Zhao, Q., & Liu, G. J. (2020) · SN Comprehensive Clinical Medicine · doi:10.1007/s42399-020-00315-y · Cited by 32
SARS-CoV-2 serology and virology trends in donors and recipients of convalescent plasma
Dulipsingh, L., Ibrahim, D., Schaefer, E. J., Crowell, R. E., Diffenderfer, M. R., Williams, K., Lima, C., McKenzie, J., Cook, L., Puff, J., et al. (2020) · Transfusion and Apheresis Science · doi:10.1016/j.transci.2020.102922 · Cited by 30
Successful Use of COVID-19 Convalescent Plasma in a Patient Recently Treated for Follicular Lymphoma
Wright, Z., Bersabe, A. R., Eden, R., Bradley, J., & Cap, A. (2020) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2020.06.012 · Cited by 29
Soleimani, Z., & Soleimani, A. (2020) · The Journal of Maternal-Fetal & Neonatal Medicine · doi:10.1080/14767058.2020.1797669 · Cited by 28
Convalescent plasma: possible therapy for novel coronavirus disease 2019
Cao, H., & Shi, Y. (2020) · Transfusion · doi:10.1111/trf.15797 · Cited by 26
Hammarström, L. L. G., Abolhassani, H., Baldanti, F., Marcotte, H., & Pan‐Hammarström, Q. (2020) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2020.04.043 · Cited by 26
Im, J. H., Nahm, C. H., Baek, J. H., Kwon, H. Y., & Lee, J. S. (2020) · Journal of Korean Medical Science · doi:10.3346/jkms.2020.35.e239 · Cited by 25
Bégin, P., Callum, J., Heddle, N. M., Cook, R. J., Zeller, M. P., Tinmouth, A. T., Fergusson, D. A., Cushing, M. M., Glesby, M. J., Chassé, M., et al. (2021) · Trials · doi:10.1186/s13063-021-05235-3 · Cited by 25
Gonzalez, J. L. B., Gámez, M. G., Enciso, E. A. M., Maldonado, R. J. E., Palacios, D. H., Campos, S. D., Robles, I. O., Guzmán, M. J. M., Díaz, A. L. G., Peña, C. M. G., et al. (2021) · medRxiv · doi:10.1101/2021.03.28.21254507 · Cited by 25
Martínez‐Reséndez, M. F., Castilleja‐Leal, F., Torres‐Quintanilla, A., Rojas‐Martínez, A., García‐Rivas, G., Ortı́z-López, R., Treviño, V., Lara-Medrano, R., Villanueva‐Lozano, H., Ramirez-Elizondo, T., et al. (2020) · medRxiv · doi:10.1101/2020.07.14.20144469 · Cited by 23
Pawar, A., Hiray, A. P., Sonawane, D. D., Bhambar, R. S., Derle, D. V., & Ahire, Y. S. (2020) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2020.05.023 · Cited by 22
Bobek, I., Gopcsa, L., Réti, M., Bekő, G., Hancz, L., Lakatos, B., Molnár, E., Nagy, S., Remenyi, P. P., Sebestyén, G., et al. (2020) · Orvosi Hetilap · doi:10.1556/650.2020.31901 · Cited by 22
Critical Illness Due to Covid-19: A Description of the Surge in a Single Center in Sioux Falls.
Jamous, F. G., Meyer, N., Buus, D., Ateeli, H., Taggart, K., Hanson, T., Alzoubaidi, M. S., Nazir, J., & Devasahayam, J. V. M. (2020) · PubMed · Cited by 22
Salman, O. H., & Mohamed, H. S. (2020) · Egyptian Journal of Anaesthesia · doi:10.1080/11101849.2020.1842087 · Cited by 22
Devos, T., Geukens, T., Schauwvlieghe, A. F. A. D., Ariën, K. K., Barbezange, C., Cleeren, M., Compernolle, V., Dauby, N., Desmecht, D. J.-M., Grimaldi, D., et al. (2020) · Trials · doi:10.1186/s13063-020-04876-0 · Cited by 19
Healthy Mother, Healthy Newborn: An Interconnected Continuum
Darmstadt, G. L., Donnay, F. A., & Starrs, A. (2013) · The Journal of Maternal-Fetal & Neonatal Medicine · doi:10.3109/14767058.2012.741154 · Cited by 15
Wang, Y., Zhang, Y., Yu, Q., & Zhu, K. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00966 · Cited by 11
Self, W. H., Stewart, T. G., Wheeler, A. P., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-227796/v1 · Cited by 2
Cited by
Agarwal, A., Mukherjee, A., Kumar, G., Chatterjee, P., Bhatnagar, T., & Malhotra, P. (2020) · BMJ · doi:10.1136/bmj.m3939 · Cited by 718
Convalescent Plasma Antibody Levels and the Risk of Death from Covid-19
Joyner, M. J., Carter, R. E., Senefeld, J. W., Klassen, S. A., Mills, J. R., Johnson, P. W., Theel, E. S., Wiggins, C. C., Bruno, K. A., Klompas, A. M., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2031893 · Cited by 509
COVID-19: breaking down a global health crisis
Mallah, S. I., Ghorab, O. K., Al-Salmi, S., Abdellatif, O. S., Tharmaratnam, T., Iskandar, M. A., Sefen, J. A. N., Sidhu, P., Atallah, B., El-Lababidi, R., et al. (2021) · Annals of Clinical Microbiology and Antimicrobials · doi:10.1186/s12941-021-00438-7 · Cited by 363
Gharbharan, A., Jordans, C. C. E., GeurtsvanKessel, C., den Hollander, J. G., Karim, F., Mollema, F. P. N., Stalenhoef – Schukken, J. E., Dofferhoff, A., Ludwig, I., Koster, A., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-23469-2 · Cited by 347
A guide to immunotherapy for COVID-19
van de Veerdonk, F. L., Giamarellos-Bourboulis, E., Pickkers, P., Derde, L., Leavis, H., van Crevel, R., Engel, J. J., Wiersinga, W. J., Vlaar, A. P. J., Shankar-Hari, M., et al. (2022) · Nature Medicine · doi:10.1038/s41591-021-01643-9 · Cited by 320
Metadata
- Authors
- Piechotta, V., Chai, K. L., Valk, S. J., Doree, C., Monsef, I., Wood, E. M., Lamikanra, A., Kimber, C., McQuilten, Z., So-Osman, C., Estcourt, L. J., & Skoetz, N.
- Venue
- Cochrane Database of Systematic Reviews
- Publisher
- Wiley
- Published
- 2020-07-10
- Volume
- 5
- Pages
- CD013600-CD013600
- ISSN
- 1361-6137 (ISSN-L)
- 1465-1858
- OpenAlex
- W3041639190
- Cited by
- 367
- References
- 163
- FWCI
- 4.96
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.